Nintedanib 50 qd [clinicaltrials_resource:NCT00514683/group/O2]
Patients were treated with 50mg nintedanib once daily
group [clinicaltrials_vocabulary:group]
NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/02e79f7bcd4df36689135e242ab0045f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/03ff3a44dff6e86616400262db86e2e2]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/06354c64d61325130395e8d64b0fee7c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0b86f104e22344b5451befa494ff0c15]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0c4da2042483f8679260a6816ca615c3]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/12d0fd6ee972d4573fdf52a06034b871]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/1e976391d4763746d5ae9c622326d963]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/21d7faf1f0747be028f52f7e09d64bf7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/232c0ac08bc811fe781d03473d11e1e7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/28cacca7fa0cebb1742f88a3e15c50e7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/31c8352785a7b62ac56bf343004c6702]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/3dd6fa3793c8dc8ad65bf735710168c3]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/3ecf4d5e943649dae2230bd9895af651]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/3fd740d7482ab3753e3215e28c5e0a03]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/40ce865c0b09d607a9876ee9314ab5a8]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/42cbef88941c37198b4d6af5681b2931]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/4f04f24274861e2f592e2426525c74f3]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/504e0af62509d62e21b56e2549df5e9d]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/50c35d7e7b7b244baf80d014e6a9ffa8]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5359b697ccf03b21ba4cab11522600b9]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5430ec5b3bd190741ba4dd6f9bf72a5d]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/54a957b86e5070b0efe00ad7b69f1aaa]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/54aee729de64eefd3f7db6f0acdc1330]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/574192f458910a0c808cbccf6c72965f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5c696e7ade2568d11888bcb3c14dc31e]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5dfa1ea30fe832cb34e188e862e64684]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/62c8bc27be430a8d644efb73675787c1]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6360177ec6698df95aaa725008e4bb96]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6551233694d953933b2c96fce74d3999]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6760e13260db9f37f4b2fdc240f9a8ae]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6c57893f4d2b023233fcae6a23f1e9eb]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/707eec31807705c54ce541b687679753]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/75aabed21e0570c739a21a1cf86ac370]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/78e2fc953b4005d8e8922d1ace6db3b5]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/7e75dd6674c2b310450d296a82a159e4]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/8224f54b83d6b3d0e409c715e6deb1a7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/831867bc33b06eaeb79013b19f518aad]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/8734751d9b5cc6b6e57ab2e8e6d48f36]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/883f24ecceb2f21b23252fb687e75ca9]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/8966cba077af94fe6c35b12f49f147bf]
group id [clinicaltrials_vocabulary:group-id]
Nintedanib 50 qd [clinicaltrials_resource:NCT00514683/group/O2]
Patients were treated with 50mg nintedanib once daily
Bio2RDF identifier
NCT00514683/group/O2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00514683/group/O2
group id [clinicaltrials_vocabulary:group-id]
description
Patients were treated with 50mg nintedanib once daily
@en
identifier
clinicaltrials_resource:NCT00514683/group/O2
title
Nintedanib 50 qd
@en
type
label
Nintedanib 50 qd [clinicaltrials_resource:NCT00514683/group/O2]
@en